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GENETIC DISORDERS – DEVELOPMENT
Detection of mutations in the COL4A5 gene by analyzing cDNA
of skin fibroblasts
FANG WANG,1 YUNFENG WANG,1 JIE DING, and JIYUN YANG
Department of Pediatrics, Peking University First Hospital, Beijing, People’s Republic of China
Detection of mutations in the COL4A5 gene by analyzing
cDNA of skin fibroblasts.
Background. Alport syndrome is a progressive hereditary
glomerulonephritis that is characterized by hematuria, sen-
sorineural deafness, ocular lesions, and progressive renal failure.
The majority of cases (about 85%) are caused by mutations in
the COL4A5 gene on the X chromosome which encodes the
type IV collagen a5 chain (X-linked Alport syndrome).
Methods. In this study we performed a systematic analysis of
the entire coding region of COL4A5 mRNA in 31 unrelated
Chinese X-linked Alport syndrome patients and four controls
by using reverse transcription-polymerase chain reaction (RT-
PCR) and direct sequencing methods. The mRNA analyzed
was isolated from cultured skin fibroblasts of Alport syndrome
patients.
Results. The entire sequences of mRNA of the controls cor-
responded exactly to the published sequence. There were 28
variants detected by analyzing mRNA of COL4A5 in 28/31 pa-
tients. Of those, a total of 25 functionally significant COL4A5
mutations was confirmed in 25/31 patients by using RT-PCR
method and subsequently confirmed at genomic DNA level,
which included seven different mutations described in previ-
ous reports, and 18 novel mutations. The mutation detection
rate was 80.6% (25/31), which is comparable with the highest
previous detection sensitivity of COL4A5 mutations in evident
X-linked Alport syndrome using genomic DNA. Furthermore,
three splicing mutations that occurred at the cryptic splice sites
and would be overlooked or simply considered as intronic se-
quence variations by solely analyzing genomic DNA were iden-
tified in this study.
Conclusion. RT-PCR and direct sequencing using cultured
skin fibroblasts RNA is a practical approach with high sensitivity
for genetic analysis in X-linked Alport syndrome patients.
Alport syndrome is a progressive hereditary glomeru-
lonephritis characterized by hematuria, sensorineural
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deafness, ocular lesions, and progressive renal failure [1].
The pathogenesis of Alport syndrome has been linked
to defects of type IV collagen, which is a major struc-
tural component of basement membranes. The major-
ity of cases (about 85%) are caused by mutations in the
COL4A5 gene on the X chromosome which encodes the
a5(IV) chain (X-linked Alport syndrome) [2]. Since the
first COL4A5 mutations were described by Barker et al
[3], more than 300 mutations of various types have been
identified in X-linked Alport syndrome patients [4–6].
At present, an integrative approach involving clinical,
histopathologic and pedigree analysis allows accurate di-
agnosis of X-linked Alport syndrome in most patients
and can be accomplished in many centers. In regards
to genetic diagnosis, most methods for COL4A5 muta-
tion screening have involved polymerase chain reaction-
single strand conformation polymorphism (PCR-SSCP)
or PCR and direct sequencing based on genomic DNA
[4–7]. Detection of mutations by reverse transcription
(RT)-PCR and direct sequencing based on the illegiti-
mate transcription of the COL4A5 gene in leukocytes
or hair roots appears to be a relatively insensitive ap-
proach [8, 9]. So far the highest total detection sensi-
tivity of COL4A5 mutations in evident X-linked Alport
syndrome (including males and females) has been about
80% using genomic DNA or RNA from leukocytes [5,
8]. However, these methods have two important disad-
vantages. First, the COL4A5 gene spans 250 kb of the
human genome and contains 51 exons. Mutation screen-
ing strategies based on genomic DNA sequencing are
quite laborious and expensive. Labor and expense are fur-
ther increased by the need to establish Epstein-Barr virus
transformed cell lines in order to extract sufficient total
RNA [8, 10]. Second, some variants are underdetected by
these methods, for instance, the intronic sequence vari-
ations that might cause splicing abnormalities as shown
by King et al [9]. Therefore, we set out to develop meth-
ods identifying COL4A5 mutations with a high rate of
sensitivity, while limiting costs associated with labor and
materials.
It has been demonstrated that a5(IV) chain distributed
in several basement membranes of the kidney, skin, and
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cochlea [11]. The immunofluorescence staining with anti-
a5(IV) antibody in the normal epidermal basement mem-
brane (EBM) also displayed the existence of mRNA and
protein encoded by COL4A5 gene [12, 13]. Several stud-
ies have documented that a1(IV), a5(IV), and a6(IV)
transcripts were expressed in cultures of dermal fibrob-
lasts [14, 15]. It was especially important that the mRNA
level of a5(IV) chain in fibroblasts of the patient with
COL4A5 mutations was similar to that of controls [15].
Therefore, we speculated that skin fibroblasts could be a
cellular source of mRNA for COL4A5 mutation analysis
in X-linked Alport syndrome.
In this study, a simple and fast approach for system-
atic gene analysis in X-linked Alport syndrome patients
was established. RT-PCR conditions were optimized to
amplify the COL4A5 cDNA in five overlapping frag-
ments from RNA isolated from skin fibroblasts. The sys-
tematic analysis of the entire coding region of COL4A5
mRNA in 31 unrelated Chinese X-linked Alport syn-
drome patients and four controls was carried out using
RT-PCR and direct sequencing. The entire sequences of
the mRNA of the controls corresponded exactly to the
published sequence [16]. A total of 25 functionally signif-
icant COL4A5 gene mutations was detected in 25/31 pa-
tients using RT-PCR method and subsequently confirmed
at the genomic DNA level. The mutation detection rate
was 80.6% (25/31). Interestingly, among 28 variants de-
tected in this study, three splicing mutations that oc-
curred at cryptic splice sites and might be missed by
genomic DNA sequencing were identified. The results
demonstrate that RT-PCR and direct sequencing using
skin fibroblasts can be applied as a sensitive and practical
method for detecting mutations in the COL4A5 gene.
METHODS
Patients
A total of 31 unrelated patients diagnosed as X-linked
Alport syndrome, 22 males and nine females, were in-
cluded in the study. The average age of these individ-
uals was 17.8 years (range 2 to 45 years). All patients
were diagnosed by fulfilling at least three of the four
diagnostic criteria for Alport syndrome as proposed by
Flinter et al [17]. In addition, each patient exhibited ab-
normal distributions of a3(IV), a4(IV) and a5(IV) chains
in the glomerular basement membrane (GBM) or abnor-
mal distribution of a5(IV) chain in the EBM [12, 18, 19].
Although, according to literatures, the abnormal stain-
ing of a(IV) chains on basement membrane is only in
70% to 80% of X-linked Alport syndrome patients [19]
(our unpublished data showed in 96% of X-linked Al-
port syndrome patients), the 31 patients in this study
were selected with the confirmed clinical diagnosis of X-
linked Alport syndrome, and were further undergone the
COL4A5 mutational analysis. The clinical features of the
patients were shown in Table 1.
Skin fibroblast cultures
After informed consent from these patients and their
family members, skin punch biopsy specimens (5 mm in
diameter and 1 mm in depth) were obtained from the
volar aspect of the forearm. Two thirds of the skin spec-
imens were for indirect immunofluorescence determina-
tion of a5(IV) chain, and the remaining one third was
used as material for cell culture. Skin biopsy specimens
obtained from four patients with other renal diseases
were used as control subjects.
The skin specimens were washed in 0.01 mol/L
phosphate-buffered saline (PBS) solution and in Dul-
becco’s modified Eagle’s medium (DMEM). Epithelium
and fat were carefully trimmed away. Then the minced
pieces of 1 to 2 mm in size were seeded in plastic flasks
with DMEM containing 20% fetal bovine serum (FBS),
L-glutamine (20 mmol/L), penicillin (100 U/mL), and
streptomycin (100 lg/mL) in an atmosphere of 95% air
and 5% carbon dioxide at 37◦C. After the outgrowth of
cells from the explant that formed a monolayer, the fi-
broblasts were passaged by trypsinization. Secondary cul-
tures were maintained in the same medium but containing
10% FBS. Cell cultures were studied in passage 3 to 8.
RNA isolation and RT
As skin fibroblasts were grown to confluence in 25 cm2
flasks, total RNA was extracted from cultured cells us-
ing Trizol reagent (Gibco, Grand Island, NY, USA)
according to the manufacturer’s instructions, and re-
verse transcribed to first-strand cDNA by using random
primers and Moloney murine leukemia virus (M-MLV)
reverse transcriptase (Promega Corporation, Madison,
WI, USA). The concentration of RNA was determined
spectrophotometrically. The integrity of RNA and the ac-
curacy of the quantitation were checked by 1% agarose
gel electrophoresis and ultraviolet light visualization.
PCR amplification of the cDNA
Five pairs of primers were designed according to the
published COL4A5 sequence [16] to amplify the en-
tire coding sequence of COL4A5 mRNA (Table 2).
The five amplified cDNA fragments were 1098 bp,
1091 bp, 1338 bp, 1207 bp, and 1017 bp in size, re-
spectively, and were partially overlapping (Fig. 1). The
PCR mixture contained (per 50 lL) cDNA template
5 lL, 1 × PCR buffer (10 mmol/L Tris-HCl, pH 9.0),
1.5 mmol/L MgCl2, 0.2 mmol/L deoxynucleoside triphos-
phate (dNTP), 0.2 lmol/L of each primer, and 2.5 units
of Taq polymerase (Promega Corporation). The PCR
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Table 1. Clinical presentations
Family Agea Family Renal Hearing Ocular Ultrastructural a5 (IV)
number Gender years historyb Hematuria Proteinuria insufficiency loss lesions changes of GBM in EBM
1 M 5 + + Trace − − − NA Absent
2 M 34 + + NA −e + NA NA Absent
3 M 28 + + + − + NA NA Absent
4 F 5 + +, G + NA − − NA Segmental
5 M 7 + + + NA − NA NA Absent
6 M 5 + + + NA + − NA Absent
7 F 33 + +, G + NA − − NA Segmental
8 M 13 + +, G +c − + − NA Absent
9 M 7 + +, G +c NA + − NA Absent
10 M 7 + +, G +c − − − NA Absent
11 F 45 + + NA NA NA NA NA Segmental
12 M 4 + + Trace NA − − NA Absent
13 M 12 + + + − − − NA Absent
14 M 21 + + +c + + − NA Absent
15 F 2 + +, G − − NA NA NA Segmental
16 M 33 + NA NA + − NA NA Absent
17 F 30 + + NA NA NA NA NA Segmental
18 F 16 + +, G − NA NA − Characteristic featured Segmental
19 M 4 + +, G − − NA NA NA Absent
20 M 39 + + + −f − NA Characteristic feature Absent
21 M 10 + +, NG +c + + NA Characteristic feature Absent
22 M 6 + + + − − − Diffuse attenuation Absent
23 M 2.5 + + + NA NA NA NA Absent
24 M 13 + + + − + − NA Absent
25 F 41 + + + + − − NA Segmental
26 M 14 + + +c − + − NA Absent
27 M 20 + + NA NA + NA NA Absent
28 M 3 + +, G + − − − NA Absent
29 M 16 + + + NA NA NA NA Absent
30 F 40 + + + NA + NA NA Segmental
31 F 38 + + + + − − NA Segmental
Abbreviations are: F, female; M, male; G, glomerular hematuria; NG, nonglomerular hematuria; NA, not available; GBM, glomerular basement membrane; EBM,
epithelial basement membrane.
aThe diagnostic age.
bFamily history of hematuria and/or end-stage renal disease.
cProteinuria with nephrotic syndrome level.
dThe pathognomonic ultrastructural feature of the Alport kidney under electron microscopy is a thickened GBM over time into multilamellations surrounding
lucent areas [2].
eDeveloped renal failure at the age of 25 years, and renal function remained normal after renal transplantation.
fDeveloped renal failure at the age of 30 years, and renal function remained normal after renal transplantation.
Table 2. Oligonucleotide primers and polymerase chain reaction (PCR) conditions for the COL4A5 cDNA analysis
Fragment Forward primer (5′-3′) Reverse primer (5′-3′) Temperature (◦C)
A TCTCTTCACCCAAGCCTCAC (69) CACCAGGGTAACCAGGATCA (1169) 58
B ACCAGGCAAAGATGGAGAAA (1099) CCGGCTGGGTTATAGTCTGA (2189) 55
C AAGGTGTGGCAGGAAATCCA (2112) ACCCTTTGGACCAGGAAGAC (3451) 58
D AAGGAACCATCGGTGATATG (3279) AGACCTGGGTCTCCTTTGC (4503) 55
E GCCTGGGCTAAAGGGTCTAC (4369) CATTGACGGCAGCAGTAGTA (5386) 55
Numbers after each primer refererd to the location of the first 5′ base according to [16].
parameters were optimized as followings: an initial de-
naturation at 95◦C for 5 minutes, 35 cycles of denatura-
tion (95◦C for 30 seconds), annealing (55◦C or 58◦C for
1 minute), elongation (72◦C for 2 minutes), and a final
elongation for 7 minutes at 72◦C. The PCR amplification
products were checked by 1% agarose gel electrophore-
sis and were subsequently sequenced with ABI Prism 377
Automated DNA Sequencer (Applera Corporation, San
Francisco, CA, USA) with both the forward and reverse
primers.
DNA analysis
When abnormal sequence was detected in the cDNA
amplification products by direct sequencing, the corre-
sponding exon with flanking intronic sequence was fur-
ther amplified to confirm the abnormality. The genomic
DNA was extracted from peripheral blood lymphocytes
by a simple salting out procedure [20] and the exons
were amplified with the published primers and conditions
with a slight modification [7]. The PCR products of exons
were determined by 1% agarose gel electrophoresis and
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Fig. 1. Strategy for amplification of the COL4A5 cDNA by RT-PCR
I: Schematic representation of the a5(IV) chain. NC1 represented non-
collagenous carboxyl-terminal domain. II: Open boxes indicated the
entire coding region of the a5(IV) chain mRNA, and the numbers in
the boxes represented the exon numbers. The horizontal line indicated
the 5′ and 3′ untranslated regions, respectively. The localizations of the
five amplified fragments were shown with the primer site (arrow heads).
then directly sequenced with DNA Sequencer as above
mentioned.
RESULTS
RNA isolation and cDNA sequence of the control
The integrity of all RNA samples was determined by
1% agarose gel electrophoresis. The purity of RNA was
confirmed with 260/280 optical density being 1.8 ∼ 2.0.
About 7 lg of total RNA could be extracted from conflu-
ent cultured skin fibroblasts in a 25 cm2 flask.
The five overlapping PCR products obtained from skin
fibroblasts of the control were successfully amplified and
completely sequenced with DNA Sequencer as above
mentioned. The sizes of all fragments were the same
as previously designed (i.e., 1098 bp, 1091 bp, 1338 bp,
1207 bp, and 1017 bp, respectively) (Fig. 2). The entire
amplified sequence of the four controls corresponded ex-
actly to the 5058 bp of the published COL4A5 mRNA
sequence, which covered part of the 5′ and 3′ untrans-
lated regions, the complete 7S, and triple-helical and
carboxyterminal NC1 domains of the collagen a5(IV)
molecule but without the variant exons 41A and 41B
[16, 21].
Detection of COL4A5 variants
A total of 28 different COL4A5 gene variants was de-
tected in 28/31 patients by using RT-PCR method and
subsequently confirmed at genomic DNA level (Table 3).
Some patients had more than one sequence variation. Of
these, 25 of the detected COL4A5 variants that were re-
vealed in 25 patients resulted in alterations in the amino
acid sequence and were classified as functionally signif-
icant mutations. The mutation detection rate was 80.6%
(25/31). Of the 28 patients, seven patients had splicing
mutations (7/28) (25.0%), three had small insertions or
M A B C D E
1375 bp
947 bp
831 bp
564 bp
Fig. 2. RT-PCR amplification of the entire coding region of COL4A5
mRNA. M: DNA molecular mass marker; Lane A to E: Fragments A
to E, respectively, PCR products obtained by the amplification of the
COL4A5 cDNA.
deletions (10.7%), 12 had missense variants (42.8%), two
had nonsense variants (7.1%) and four patients had more
variants in one allele (14.4%). Seven splicing mutations,
six missense variants, three small insertion/deletions, two
nonsense variants, and three haplotypes were newly de-
scribed in the present study. The other seven variants have
already been reported elsewhere (Table 3).
Splicing mutations
Seven mutations (25.0%) were identified in introns that
affected splice signals and resulted in aberrant splicing of
mRNA, causing complete or partial exon skipping. Four
of the splicing mutations were located in the two most
highly conserved 5′ donor nucleotides or 3′ acceptor nu-
cleotides (↓GT or AG↓). The acceptor splice site muta-
tion 1626 − 1G>A in family 3 resulted in skipping of the
downstream exon 22. Mutations in splice donor sites in
intron 25 (family 6) and in intron 46 (family 7), resulted
in skipping of the upstream exon 25 and partial skipping
of exon 46, respectively. In the case of the mutation in
splice donor site 1718 + 1G>A in intron 22, two kinds of
aberrant mRNA were induced: skipping of the upstream
exon 22 and skipping of the upstream exon 22 along with
the insertion of 44 bp of intron 21.
Interestingly, three splicing mutations (10.7%) occur-
ring at atypical or cryptic splice sites were identified in the
study. The mutation 1036 + 5G>T in intron 14 resulted
in the loss of upstream exon 14 and the mutation 1625 +
56 1625 + 57insC led to partial skipping of upstream
exon 22. The mutation 668 − 12G>A (family 1) also in-
duced two kinds of aberrant mRNA: skipping of the up-
stream exon 9 and preserving exon 9 but inserting 10 bp of
intron 8.
Small insertion/deletions
A single base insertion and two small deletions were
found. Two of them (1486 1487insG and 1855 1856delC)
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Table 3. COL4A5 sequence variants identified in the study
Family RNA levela DNA levelb Protein levela
number (experimentally determined) (experimentally determined) Exon/Intron (changes deduced only) Previously reported
Splicing mutations (7)
1 [r.667 668 ins 668–1 668–10,
r.668 748del]
g.668 − 12G>A Intron 8 [p. E157X, p. G156 Q182del]
2 r.983 1036del g.1036 + 5G>T Intron 14 p. G261 P278del
3 r.1626 1718del g.1626 − 1G>A Intron 21 p. G475 P505del
4 r.1590 1625del g.1625 + 56 1625 + 57ins Intron 21 p. G463 K474del
5 [r.1626 1718del,
r.1626 1718delins1625 +
g.1718 + 1G>A Intron 22 [p. G475 P505del,
? 1625 + ? + 43] p. G475 P505del; p. M556X]
6 r.1982 2150del g.2150 + 1G>A Intron 25 [p. G594 P649del; p. I659X]
7 r.4478 4495del g.4499 + 1G>A Intron 46 p. P1426 Q1431del
Small insertion/deletions (3)
8 r.1486 1487ins g.1486 1487ins 20 p. P446X
9 r.1855 1856del g.1855 1856del 24 p. G555X
10 r.2752 2775del g.2752 2775del 31 p. P851 P858del
Substitutions-missense variants (13)
11 r.731g>c g.731G>C 9 p.G177R Renieri et al (1996)
12 r.1175g>a, r.2309a>g g.1175G>A, g.2309A>G 17, 27 p.G325R, p.I703V Knebelmann et al (1992) (G325R)
13 r.1393c>g, r.1410g>u g.1393C>G, g.1410G>T 20, 20 p.G397G, p.G403V
14 r.2207g>c g.2207G>C 26 p.G669R Plant et al (1999)
15 r.3060g>u g.3060G>T 33 p.G953V Knebelmann et al (1996)
16 r.3246g>u g.3246G>T 35 p.G1015V Knebelmann et al (1996)
17 r.3282g>u g.3282G>T 35 p.G1027V
18 r.3290g>a g.3290G>A 35 p.G1030S Martin et al (1998)
19 r.3896g>a g.3896G>A 41 p.G1232S
20 r.4544g>a g.4544G>A 47 p.G1448S
21 r.4959g>u g.4959G>T 49 p.C1586F
22 r.5244g>u g.5244G>T 51 p.C1681F
Substitutions-nonsense variants (2)
23 r.998c>u g.998C>T 14 p.R266X
24 r.2990c>u g.2990C>T 33 p.Q930X
Substitutions-more variants in one allele (4)
25 r.2257u>c, r. 2551g>a, r.3060g>u g.2257T>C, g.2551G>A,
g.3060G>T
27, 29, 33 p.L685L, p.P783P, p.G953V
26 r.1297g>c, r. 1533u>g, r.2551g>a,
r.2257u>c, r.3715a>g
g.1297G>C, g.1533T>G, g.2551G>A,
g.2257T>C, g.3715A>G
19, 20, 27, 29, 39 p.G365G, p.I444S, p.L685L,
p.P783P, p.Q1171Q
27 r.1297g>c, r.1533u>g, r.2551g>a,
r.2257u>c, r.3715a>g
g.1297G>C, g.1533T>G, g.2551G>A,
g.2257T>C, g.3715A>G
19, 20, 27, 29, 39 p.G365G, p.I444S, p.L685L,
p.P783P, p.Q1171Q
28 r.1297g>c, r.1533u>g, r.2551g>a,
r.2257u>c, r.3715a>g, r.4478c>u
g.1297G>C, g.1533T>G, g.2551G>A,
g.2257T>C, g.3715A>G, g.4478C>T
19, 20, 27, 29, 39, 46 p.G365G, p.I444S, p.L685L,
p.P783P, p.Q1171Q, p.D1425D
Inoue et al (1999)
aNuleotides and amino acids were numbered according to [22].
bNucleotides were numbered according to [16].
Wang and Wang et al: COL4A5 detection using cDNA of skin fibroblasts 1273
caused a change in the reading frame and introduced a
premature stop codon. These variants were expected to
result in truncated a5(IV) chains. One in-frame deletion
was found in exon 31 in family 10.
Missense variants
Thirteen different missense variants were identified in
the transcript and were confirmed by genomic DNA anal-
ysis in family 11 to family 22. Among 11 different amino
acid substitutions detected in the collagenous domain of
a5(IV) chain, 10 were glycine substitutions which inter-
rupt the Gly-X-Y repeat structure and disrupt folding
of the triple helix. G953V was found in two apparently
unrelated families and one family also had other vari-
ants. In family 12 there were two amino acid substitutions
(G325R and I703V) identified. The substitution G325R
has been identified as a causative mutation in X-linked
Alport syndrome patient [23], whereas the pathogenicity
of the substitution I703V was not established yet in the
study. Two cysteine codon changes were detected in exon
49 and 51, respectively.
Nonsense variants
Two single base substitutions resulted in the generation
of a stop codon and therefore the truncation of the a5(IV)
protein.
More variants in one allele
Six “silent” variants identified in the study were nu-
cleotide changes at the third base of codons. Interest-
ingly, four of the six “silent” variants (G365G + L685L +
P783P + Q1171Q) were found on the same allele as the
I444S variant and were found in three unrelated families
(26, 27, and 28). The I444S variant has been previously
reported a polymorphism but not a pathogenic change
[24]. In one case the “silent” variant D1425D was also
present and this haplotype has already been detected [8].
The haplotype L685L + P783P + G953V found in family
25 and another haplotype G365G + I444S + L685L +
P783P + Q1171Q found in both family 26 and family 27
have never been reported previously.
DISCUSSION
Alport syndrome is a clinically heterogeneous, inher-
ited disorder of the GBM. The vast majority of Alport
pedigrees show X-linked inheritance which is caused by
mutations in the COL4A5 gene encoding a5(IV) chain.
As the expression patterns of a5(IV) chain are nearly al-
ways identical in the GBM and EBM, and compared with
a kidney biopsy, a skin biopsy is less invasive, immuno-
histochemical analysis of skin biopsy specimens with anti-
a5(IV) antibody is a useful method to identify a COL4A5
gene defect [12, 13]. In our clinical practice, skin biopsy
and indirect immunofluorescent analysis of a5(IV) chain
in the EBM are performed routinely on patients sus-
pected of X-linked Alport syndrome. At the same time,
only a tiny piece of the skin specimen was enough to
culture skin fibroblasts for RNA isolation and mutation
analysis.
RT-PCR and direct sequencing from COL4A5 mRNA
isolated from cultured skin fibroblasts were performed in
31 unrelated patients diagnosed as X-linked Alport syn-
drome. Variants that were predicted to be functionally
significant were identified in 25 of the 31 patients in the
present work. The mutation detection rate was 80.6%,
comparable with the highest previous detection sensitiv-
ity of COL4A5 mutations in evident X-linked Alport syn-
drome using genomic DNA or leukocytes [5, 8]. These
results show that RT-PCR and direct sequencing using
skin fibroblasts RNA is a highly sensitive method for the
routine genetic diagnosis of X-linked Alport syndrome
patients. Each mutation identified in the study by RT-
PCR and direct sequencing was confirmed on genomic
DNA level, which suggested that this approach was reli-
able and consistent. Furthermore, this approach was sim-
pler and more convenient methodologically comparing
with the method that isolated total RNA from Epstein-
Barr virus–transformed lymphocytes [8, 10]. RT-PCR and
direct sequencing using RNA isolated from skin fibrob-
lasts is much more economical than PCR-SSCP, direct
sequencing of genomic DNA or RT-PCR/sequencing of
lymphocyte RNA. Only five fragments covering the en-
tire coding sequence of COL4A5 gene were sufficient
for our technique, whereas previous methods of analyz-
ing genomic DNA needed to amplify and sequence 51
exons. The material costs of identifying mutations with
RNA isolated from skin fibroblasts is approximately 1/6
to 1/7 of that of performing PCR and direct sequencing
with genomic DNA according to our experience and the
expense in our laboratory (data not shown). Therefore,
we believe our approach is more suitable and practical
for institutions or laboratories with limited financial re-
sources. A disadvantage of our approach is the time re-
quired for cell culture (3 to 4 weeks according to our own
experience).
In the study, 28 variants were identified in 28 patients,
including seven variants described in previous reports [4,
7, 23–26], and 21 novel variants. All variants were scat-
tered throughout the entire coding region and involved
19 of the 51 exons. No hot spot area for mutations has
been detected.
Seven splicing mutations (25.0%) were detected in the
study. It is notable that three of seven splicing mutations
(3/28) (10.7%) occurred at atypical or cryptic splice sites
[i.e., the mutation sites that affected the splice signal lo-
cated in the introns sequence except the typical splice
donor and acceptor sites (↓GT or AG↓)]. It is shown from
the present results that splicing mutations in COL4A5 are
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not always located at typical splice sites. In addition, in
some cases single base mutations in exons could cause
aberrant splicing in the transcript [4, 5]. It can be spec-
ulated that screening for COL4A5 mutations solely by
PCR and direct sequencing using genomic DNA could
overlook 10% ∼ 12.5% of cryptic splicing mutations [9].
The higher mutation detection rate in this study may
be attributable to the detection of cryptic splicing mu-
tations using RT-PCR and direct sequencing from skin
fibroblasts.
It has been reported that alternatively splicing of
COL4A5 mRNA existed in mRNAs from a variety of tis-
sues. Besides the predominant isoform, there were two
variants that differed from the predominant isoform by
using alternative exons 41A and 41B and having one
or two additional Gly-X-Y repeats [10, 21]. These vari-
ants were detected in leukocytes, kidney, placenta, liver,
spleen, and thymus epithelia. The finding of differential
splicing of COL4A5 mRNA in these tissues might affect
their use of these tissues for the analysis of Alport vari-
ants. However, no alternatively splicing variants with 41A
and/or 41B exons were found in the four controls and 31
X-linked Alport syndrome patients in the present study.
On the basis of the above results, we have shown that
RT-PCR and direct sequencing using cultured skin fibrob-
lasts RNA is a practical and feasible approach with high
sensitivity for analysis of COL4A5 gene variants in X-
linked Alport syndrome patients.
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